Zhou P, Qian H, Zhu P, Ben J, Chen G, Chen Q
Front Oncol. 2025; 14:1485681.
PMID: 39927116
PMC: 11803464.
DOI: 10.3389/fonc.2024.1485681.
Mousavi-Kiasary S, Bayat M, Abbasvandi F, Khoundabi B, Mousavi F, Akbari A
Sci Rep. 2025; 15(1):4571.
PMID: 39915527
PMC: 11802794.
DOI: 10.1038/s41598-024-84115-7.
Arenas M, Bolukbasi Y, Boersma L, Offersen B, Kouloulias V, Palumbo I
Breast. 2025; 80:103881.
PMID: 39854807
PMC: 11804728.
DOI: 10.1016/j.breast.2025.103881.
Gasparri M, Kaidar-Person O, Gentilini O, de Boniface J, Kuehn T, Poortmans P
Radiat Oncol J. 2025; 42(4):308-318.
PMID: 39748531
PMC: 11701460.
DOI: 10.3857/roj.2024.00248.
Abbasvandi F, Mahdavi R, Bayat M, Hajighasemi F, Jahanbakhshi F, Aghaei F
Sci Rep. 2024; 14(1):12900.
PMID: 38839807
PMC: 11153595.
DOI: 10.1038/s41598-024-61600-7.
Prognostic Importance of Axillary Lymph Node Response to Neoadjuvant Systemic Therapy on Axillary Surgery in Breast Cancer-A Single Center Experience.
Grasic Kuhar C, Geiger J, Schwab F, Heinzelmann-Schwartz V, Vetter M, Weber W
Cancers (Basel). 2024; 16(7).
PMID: 38610984
PMC: 11010874.
DOI: 10.3390/cancers16071306.
An ultrasound-based nomogram model in the assessment of pathological complete response of neoadjuvant chemotherapy in breast cancer.
Liu J, Leng X, Liu W, Ma Y, Qiu L, Zumureti T
Front Oncol. 2024; 14:1285511.
PMID: 38500656
PMC: 10946249.
DOI: 10.3389/fonc.2024.1285511.
Role of beta-(1→3)(1→6)-D-glucan derived from yeast on natural killer (NK) cells and breast cancer cell lines in 2D and 3D cultures.
Boulifa A, Raftery M, Franzen A, Radecke C, Stintzing S, Blohmer J
BMC Cancer. 2024; 24(1):339.
PMID: 38486205
PMC: 10938759.
DOI: 10.1186/s12885-024-11979-3.
Prognostic analysis of cT1-3N1M0 breast cancer patients who have responded to neoadjuvant therapy undergoing various axillary surgery and breast surgery based on propensity score matching and competitive risk model.
Zhang M, Sun Y, Wu H, Xiao J, Chen W, Wang H
Front Oncol. 2024; 14:1319981.
PMID: 38327751
PMC: 10847357.
DOI: 10.3389/fonc.2024.1319981.
Breast cancer: evaluating the axilla before, during, and after therapy-new challenges.
Steyerova P, Kaidar-Person O, Pinker K, Dubsky P
Eur Radiol. 2024; 34(8):5461-5463.
PMID: 38276979
DOI: 10.1007/s00330-024-10621-x.
LINC00467 mediates the 5-fluorouracil resistance in breast cancer cells.
Li L, Zhang Y, Zhan Y, Zhong Y, Li X
In Vitro Cell Dev Biol Anim. 2023; 60(1):80-88.
PMID: 38127229
DOI: 10.1007/s11626-023-00832-9.
Neoadjuvant chemotherapy for breast cancer: an evaluation of its efficacy and research progress.
Chen Y, Qi Y, Wang K
Front Oncol. 2023; 13:1169010.
PMID: 37854685
PMC: 10579937.
DOI: 10.3389/fonc.2023.1169010.
Update on DWI for Breast Cancer Diagnosis and Treatment Monitoring.
Gullo R, Partridge S, Shin H, Thakur S, Pinker K
AJR Am J Roentgenol. 2023; 222(1):e2329933.
PMID: 37850579
PMC: 11196747.
DOI: 10.2214/AJR.23.29933.
The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensus.
Kaidar-Person O, Pfob A, Gentilini O, Borisch B, Bosch A, Cardoso M
EClinicalMedicine. 2023; 61:102085.
PMID: 37528842
PMC: 10388578.
DOI: 10.1016/j.eclinm.2023.102085.
Breast-conserving surgery versus mastectomy for treatment of breast cancer after neoadjuvant chemotherapy.
Song Y, Huang Z, Fang H, Tang Y, Jing H, Song Y
Front Oncol. 2023; 13:1178230.
PMID: 37496664
PMC: 10368492.
DOI: 10.3389/fonc.2023.1178230.
Artificial Intelligence-Enhanced Breast MRI: Applications in Breast Cancer Primary Treatment Response Assessment and Prediction.
Gullo R, Marcus E, Huayanay J, Eskreis-Winkler S, Thakur S, Teuwen J
Invest Radiol. 2023; 59(3):230-242.
PMID: 37493391
PMC: 10818006.
DOI: 10.1097/RLI.0000000000001010.
Staging of the Axilla After Neoadjuvant Chemotherapy: Which Technique is Better? The Endless Debate.
Montagna G, El-Tamer M
Ann Surg Oncol. 2023; 30(11):6290-6292.
PMID: 37394672
DOI: 10.1245/s10434-023-13805-9.
Uncertainties and controversies in axillary management of patients with breast cancer.
Weber W, Gentilini O, Morrow M, Montagna G, de Boniface J, Fitzal F
Cancer Treat Rev. 2023; 117:102556.
PMID: 37126938
PMC: 10752145.
DOI: 10.1016/j.ctrv.2023.102556.
The underused potential of breast conserving therapy after neoadjuvant system treatment - Causes and solutions.
Pfob A, Dubsky P
Breast. 2023; 67:110-115.
PMID: 36669994
PMC: 9982288.
DOI: 10.1016/j.breast.2023.01.008.
Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer.
Agostinetto E, Jacobs F, Debien V, De Caluwe A, Pop C, Catteau X
Cancers (Basel). 2022; 14(21).
PMID: 36358886
PMC: 9654353.
DOI: 10.3390/cancers14215467.